Finally, the group emphasized that ADs are not a solution for inadequate planning, but are meant to enhance study efficiency while maintaining validity and integrity.
"The US Food and Drug Administration (FDA) released a draft version of the``Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics""[ 3]."